US · Healthcare · Medical Instruments & Supplies
EPS came in at -0.32 against a street estimate of -0.35 — a beat of 8.6%.
Analysts rate Pulse Biosciences Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $62.33.
CONFIDENT Pulse crushed IDE enrollment (82 patients vs. 145 target), accelerated completion to early Q4. Raised $57.5M; cash now $101.6M. Vybrance thyroid revenue modest at $434K, but catheter momentum extraordinary with physicians doing 7 cases/day. Q2 2026 Call did not discuss regional performance. EU feasibility data mentioned for catheter & clamp; U.S. pivotal IDEs primary focus. Analysts pressed on 12-month data readiness (LaViolette: long pole acceptable given velocity), site caps (confirmed 15%, some maxed, new ones opening), and mapping integration (EnSite to remain; CARTO speculation unconfirmed). Management emphasized physician enthusiasm & acute differentiation as market drivers independent of long-term outcome parity. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 2.06% |
| Bank of America Corp | 2.03% |
| Vanguard Capital Management, LLC | 1.11% |
| Portolan Capital Management, LLC | 1.06% |
| T. Rowe Price Associates, Inc. | 1.05% |
| Balyasny Asset Management LLC | 1.01% |
| Citadel Advisors Llc | 0.88% |
| Geode Capital Management, LLC | 0.75% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 product revenue was $395,000, compared with $86,000 in the third quarter of 2025. • Nine-month 2026 product re | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $0.4 million, up from $0.1 million in Q3 2025. • GAAP net loss was ($23.1) million, compared with ($19.4) mil | 2026-11-05 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • Pulse Biosciences, Inc. announced a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocr | 2026-10-14 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • Pulse Biosciences announced it reached its enrollment target of 164 evaluable patients in the NANOPULSE-AF clinical study. • The | 2026-10-07 |
| Material agreement · Q3 2026 PULSE BIOSCIENCES, INC. (PLSE) – FORM 8-K SUMMARY HEADLINE NUMBERS • Company entered into new equity distribution agreement on September 15, 2026 fo | 2026-09-15 |
| Company announcement · Q3 2026 PULSE BIOSCIENCES, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Pulse Biosciences completed patient enrollment in its PRECISE-BTN clinica | 2026-09-15 |
| Quarterly report · Q2 2026 PULSE BIOSCIENCES, INC. – 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash position: $101.6 million as of June 30, 2026 (up | 2026-08-06 |
| Material agreement · Q3 2026 PULSE BIOSCIENCES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company established equity distribution agreement on August 6, 2026 with Mizuho Securi | 2026-08-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Commercial and clinical partnership expands thyroid treatment use and clinical data generation Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. The center will use Pulse’s nPulse Vybrance Percutaneous Electrode System | 2026-10-14 |
| Reallocates capital to accelerate cardiac catheter program development Pulse Biosciences announced a strategic shift to prioritize its cardiac catheter ablation program for treating atrial fibrillation (AFib) after impressive clinical results. The company prese | 2026-03-17 |
| Initiates research collaboration with MD Anderson Cancer Center for thyroid tumor treatment Pulse Biosciences announced a research collaboration with MD Anderson Cancer Center to study its nPulse technology for treating thyroid tumors. The FDA approved an Investigational Device Exe | 2025-12-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pulse Biosciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.